Verition Fund Management LLC Fibrogen Inc Transaction History

Verition Fund Management LLC

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	BUY	$0.89 - $2.36 $84,553 - $224,209	95,004 New	95,004 $84,000
Q2 2023 Aug 14, 2023	BUY	$2.49 - $20.59 $35,109 - $290,319	14,100 New	14,100 $38,000
Q1 2022 May 13, 2022	SELL	$12.02 - $16.79 $4.14 Million - $5.78 Million	-344,091 Closed	0 $0
Q4 2021 Feb 14, 2022	BUY	$9.93 - $15.39 $3.24 Million - $5.02 Million	326,391 Added 1844.02%	344,091 $4.85 Million
Q3 2021 Nov 15, 2021	SELL	$10.18 - $26.64 $71,819 - $187,945	-7,055 Reduced 28.5%	17,700 $181,000
Q3 2020 Nov 16, 2020	SELL	$40.47 - $45.5 $544,159 - $611,793	-13,446 Reduced 35.2%	24,755 $1.02 Million
Q2 2020 Aug 14, 2020	BUY	$32.57 - $42.83 $1.24 Million - $1.64 Million	38,201 New	38,201 $1.55 Million
Q1 2020 May 15, 2020	SELL	$23.3 - $45.96 $915,853 - $1.81 Million	-39,307 Closed	0 $0
Q4 2019 Feb 14, 2020	SELL	$34.58 - $48.06 $62,001 - $86,171	-1,793 Reduced 4.36%	39,307 $1.69 Million
Q2 2019 Aug 14, 2019	BUY	$35.13 - $55.53 $1.44 Million - $2.28 Million	41,100 New	41,100 $1.86 Million
Q4 2017 Feb 15, 2018	SELL	$41.95 - $60.1 $157,354 - $225,435	-3,751 Closed	0 $0
Q3 2017 Nov 14, 2017	BUY	$33.4 - $53.9 $125,283 - $202,178	3,751	3,751 $202,000

47.1M

387K

672K

Ticker FGEN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 93,741,200
Market Cap $32.8M
Description
FibroGen, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. The company is developing Roxadustat, an oral small molecule inhibitor of hypoxia inducible factor prolyl hydroxylases, which has completed Phase III clinical development for the treatment of anemia in chronic k...

Get notified when there are updates to the investment portfolio of Verition Fund Management LLC, based on Form 13F filings with the SEC.

Stay updated on Verition Fund Management LLC with notifications on news.